PeptideDB

Pioglitazone potassium

CAS No.: 1266523-09-4

Pioglitazone potassium (U 72107) is an orally active and selective agonist of peroxisome proliferator-activated receptor
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Description Pioglitazone potassium (U 72107) is an orally active and selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ). It demonstrates high affinity binding to the ligand-binding domain of PPARγ, with an EC50 of 0.93 μM and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone potassium has applications in diabetes research [2] [3] [4].
In vitro Pioglitazone potassium (0.5 or 1 μM, 5 days) can completely prevent AGEs (advanced glycation end-products)-induced β-cell necrosis and the increase of caspase-3 thereby avoiding the impaired viability caused by AGEs in pancreatic beta cell line HIT-T15 [2]. Pioglitazone potassium (1 μM, 1 h) can stimulate insulin secretion induced by low glucose concentration and attenuate the GSSG/GSH ratio in cells cultured with AGEs [2].
In vivo Pioglitazone potassium (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle [3]. Pioglitazone potassium (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia [4]. Animal Model: ob/ob and adipo -/- ob/ob mice with a C57Bl/6 background [3] Dosage: 10 or 30 mg/kg Administration: Oral gavage; once daily; 14 days Result: Showed no changes of serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo -/- ob/ob C57BL/6 mice at 10 mg/kg but significantly reduced to a similar degree at 30 mg/kg. Also showed no changes of expressions of TNFα and resistin in adipose tissues of ob/ob and adipo -/- ob/ob mice at 10 mg/kg but decreased at 30 mg/kg. Animal Model: Male Wistar albino rats [4] Dosage: 10 mg/kg Administration: Oral gavage; once daily; 4 weeks Result: Decreased the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB), TGF-β1 gene expression and regulated the expression of MMP-2/TIMP-2 system.
molecular weight 394.53
Molecular formula C19H19KN2O3S
CAS 1266523-09-4
Storage Powder: -20°C for 3 years | In solvent: -80°C for 1 year